Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aditxt, Inc. (NASDAQ: ADTX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Aditxt describes its business as a social innovation platform accelerating promising health innovations, as well as its governance, capital structure, and key agreements.
Through Forms 10-K and 10-Q, investors can review Aditxt’s periodic financial statements and management discussions, including information about its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health. When Aditxt files a Form 12b-25 (NT 10-Q), it provides an explanation for delayed quarterly reports and indicates the expected timing of the filing.
Current reports on Form 8-K document material events such as the implementation of a 1-for-113 reverse stock split, amendments to the certificate of incorporation, entry into or termination of material definitive agreements, and financing arrangements. For example, Aditxt has used Form 8-K to report the approval and effectuation of its reverse stock split, the termination of its Amended and Restated Merger Agreement with Evofem Biosciences, Inc., and the issuance of notes and other securities.
Proxy statements on Schedule 14A (such as definitive proxy statements for special meetings) detail proposals submitted to stockholders, including approvals for issuances of common stock underlying various series of convertible preferred stock and warrants, the adoption of an Employee Stock Purchase Plan, amendments to the company’s equity incentive plan, authority to effect a reverse stock split, and a non-binding advisory vote on a proposed name change to “bitXbio, Inc.” These documents also describe meeting logistics and voting procedures.
Investors interested in ownership and governance can review information on security ownership of certain beneficial owners and management within proxy materials, while exhibits to Forms 8-K and other reports may include key agreements, amendments, and certificates of amendment. Stock Titan’s interface surfaces these filings as they appear on EDGAR and can pair them with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex items such as capital structure changes, equity plans, and material contracts.
For those tracking insider and security-holder activity, related forms and disclosures filed by Aditxt and its insiders can be viewed alongside the company’s core reports. Together, these filings form the primary regulatory record of how Aditxt presents its strategy, risk factors, and significant corporate actions to the market.
Aditxt, Inc. held a reconvened special meeting of stockholders on February 13, 2026, after adjourning the original January 30, 2026 virtual meeting to allow more time for voting. A total of 516,567 shares of common stock, representing 33.39% of the voting authority, were present virtually, in person, or by proxy, which constituted a quorum.
Stockholders voted on several matters, with detailed results reported for each item, including votes for, against, abstain, and broker non-votes. One proposal received 455,456 votes for and 40,462 against, and another received 424,426 votes for and 75,505 against, indicating substantial participation across the agenda items.
Aditxt, Inc. shareholder Eugene Reagan Dunn filed a Schedule 13G reporting beneficial ownership of 156,300 shares of Aditxt common stock, representing 8.7% of the class. He reports sole voting and dispositive power over all these shares and no shared authority.
The filing states that the securities were not acquired for the purpose of changing or influencing control of Aditxt and are not held in connection with any control-related transaction, other than activities solely in connection with a nomination under applicable proxy rules.
Aditxt, Inc. adjourned its special stockholder meeting to February 13, 2026 to allow more time for voting on several key proposals affecting its capital structure and corporate identity.
Stockholders are being asked to approve issuances of common stock underlying Series A-1 and Series C-1 preferred shares and related warrants, a new 2025 Employee Stock Purchase Plan, and an amendment to the 2021 Omnibus Equity Incentive Plan to increase issuable shares to 350,000. They are also considering an advisory vote on changing the company’s name to bitXbio, Inc. and granting the board discretion to implement a reverse stock split between 1-for-5 and 1-for-250 within one year of approval.
Aditxt, Inc. reported that Nasdaq has granted extra time to regain compliance with Nasdaq Listing Rule 5550(b), which requires minimum stockholders’ equity of
The extension depends on Aditxt completing financing transactions and, on or before
If Aditxt does not show compliance with the rule when it files its periodic report for the period ending
Aditxt, Inc. is calling a virtual special stockholder meeting on January 30, 2026 to approve several significant capital and governance changes. Stockholders will vote on approvals related to prior financings, including issuances tied to Series A-1 and Series C-1 convertible preferred stock and multiple warrant agreements, as required by Nasdaq rules. They are also being asked to adopt a 2025 Employee Stock Purchase Plan reserving 200,000 shares and to increase the 2021 Omnibus Equity Incentive Plan share pool to 350,000 shares, which the company states would equal about 19.7% of its common stock. Additional proposals would change the corporate name to “bitXbio, Inc.”, authorize the board to implement a reverse stock split at a ratio between one-for-five (1:5) and one-for-two hundred fifty (1:250) within one year, and permit adjournment of the meeting to solicit more proxies if needed. Holders of Aditxt’s 1,776,023 outstanding common shares as of December 5, 2025 are entitled to one vote per share.
The company filed a prospectus supplement to increase the capacity of its at-the-market common stock offering to up to $20,000,000 in aggregate gross sales, not including shares previously sold, under its existing agreement with H.C. Wainwright & Co., LLC as sales agent.
Previously, the company had registered up to $35,000,000 of common stock for sales under this program, later reduced to $11,840,454, and it has already sold 1,370,607 shares for aggregate gross proceeds of $17,771,951 under prior prospectus supplements. The supplement also notes that the company is currently no longer subject to the offering limits in General Instruction I.B.6 of Form S-3, and that its common stock trades on the Nasdaq Capital Market under the symbol ADTX, where the last reported sale price was $2.24 per share on December 12, 2025.
Aditxt, Inc. (ADTX) reported an insider transaction by its Chief M&A Officer on a Form 4. On 11/25/2025, the officer sold 1 share of Aditxt common stock at a price of $3.2 per share in a transaction coded "S" for sale. After this small tax-related sale, the reporting person held 0 shares of Aditxt common stock directly. The explanation notes that the share was sold for tax-related purposes.
Aditxt, Inc. reported that on November 18, 2025 it issued a press release describing its bitXbio™ strategy and announcing the filing of a preliminary proxy statement on Schedule 14A for a special meeting of stockholders. The proxy statement includes proposals related to the Company’s Employee Stock Purchase Plan and a non-binding advisory vote on amending its Certificate of Incorporation to change the corporate name from “Aditxt, Inc.” to “bitXbio, Inc.” The press release is included as Exhibit 99.1 and incorporated by reference.
Aditxt, Inc. (ADTX) reported very limited revenue and heavy losses in its latest quarter. For the nine months ended September 30, 2025, sales were only $2,770, while the company recorded a net loss of $37,555,792 and used $16,442,686 of cash in operating activities.
Cash on hand was just $163,041, against total liabilities of $20,658,817, resulting in a stockholders’ equity deficit of $8,859,178. Management states there is substantial doubt about Aditxt’s ability to continue as a going concern and notes constraints on raising capital under the Form S-3 “baby shelf” limitation.
A major driver of the loss was a $23,001,919 impairment on its Evofem F-1 Preferred Stock investment, reducing the Evofem-related balance to $7,051,933. The company also faces high-cost debt, lease payment arrears, multiple recent reverse stock splits, and warns that a potential Nasdaq delisting could further hurt liquidity, valuation, and access to financing.
Aditxt, Inc. (ADTX) submitted a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states that the compilation, dissemination and review of the information required for the quarterly report created time constraints that made a timely filing impracticable without undue hardship and expense. Aditxt states that it undertakes the responsibility to file the Form 10-Q no later than 5 days after its original due date under the Rule 12b-25 extension framework.